Immunology
Atopic Dermatitis: How Far Does Treatment Reach?
Can treating the skin change what comes next? This edition opens with a 3,525-patient meta-analysis asking whether new and worsening allergic events can be held back, follows infants and young children through two years of continuous treatment, and closes with what 5,279 patients reveal about anti-drug antibodies and whether they matter.
Atopic Dermatitis: Beyond Symptom Control
What does three years on treatment actually look like? Can relieving itch reshape the nervous system itself? Do topical steroids leave the atopic march unaddressed? And what changes beneath the skin of children under six? Four new studies take these questions on.
Atopic Dermatitis: Real-World Evidence in Focus
Three new papers on atopic dermatitis. What happens when patients in control move to less frequent dosing, how the biologic class compares across trials and real-world use, and what the pooled evidence shows in patients aged 60 and over.
Can Atopic Dermatitis Be Modified, Not Just Managed?
Remission that holds after treatment stops is no longer a hypothetical. This edition opens with a review defining what disease modification in atopic dermatitis would actually require, then looks at what the evidence shows so far: sustained benefit in patients over 60, whether treating children early can change where the atopic march ends, and what happens to skin nerves and barrier proteins after 16 weeks of treatment.
Safety Profile: 5 years of Open Label Extension Study (OLE)
DUPIXENT has demonstrated a consistent safety profile in adults with moderate-to- severe AD, supported by five years of clinical trial data and real-world evidence across all age groups from 6 months through adulthood.1
Improving Airway Function in Type 2 Inflammation, Insights from global respiratory expert
Atopic Dermatitis: What Changes Beneath the Surface
In this issue, we feature three studies that provide insights into disease modification in atopic dermatitis, examining microbiome restoration, long-term infection outcomes in real-world practice, and clinical responses in erythrodermic presentations.
Atopic Dermatitis: Disease Modification in Focus
Curated evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children.
Please log in or register to continue reading.
Login For Healthcare Professionals
HCP Verification Required
We are in the midst of verifying your registration. You will receive an email confirmation to access Campus Sanofi once your verification is complete.
RESEND SUCCESS
Please check you email for verification emali.
Restricted Content
You do not have the correct verified role to view this content.
You are almost set!
Success
Thank you for registering. Please validate your email by clicking on the link in the email sent to you. Once your registration has been validated, you will receive a confirmation email to log in to Campus Sanofi.
Patient-Video
Request-form